Back to the main directory
EarningsReview / Equity
- Interim CEO appointed as permanent CEO by BNP Paribas Exane
- YIT (Sell, TP: EUR1.40) - A bandage, not a remedy by DnB Markets
- Demant (Buy, TP: DKK400.00) - Improved long-term outlook by DnB Markets
- US shale: Overspend stalls growth by DnB Markets
- Back to Football by BNP Paribas Exane
- All gas, no brakes by BNP Paribas Exane
- Q4 23 wrap-up: Proceed with caution by BNP Paribas Exane
- Demant - Coherent CMD message, but beware of Q1 slowdown by Danske Bank Equity Research
- FY24 guide looks sensible with risk skewed to upside by BNP Paribas Exane
- FY23 preview: Pricing and GenAI tailwinds to gather pace by BNP Paribas Exane
- Three CEOs walk into a bar by BNP Paribas Exane
- INVEST SECURITIES - AFFLUENT MEDICAL : Artus rentre finalement en clinique - ACHAT, OC 3,2€ vs 3,5€ by Invest Securities
- Esprinet - 2023 difficile pour le secteur by MidCap Partners
- Lumibird - EBITDA au-delà des attentes, témoignage de la force du modèle by MidCap Partners
- Neodecortech - FY 2023 Results: Revenue Down, but Margins Up by MidCap Partners
- Esprinet - 2023: a Challenging Year for the Sector by MidCap Partners
- VOLKSWAGEN AG: RDOS. 4T’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- 4imprint Group - Continued market share gains by Edison Investment Research
- INDITEX: RDOS. 4T’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- De'Longhi - COFFEE ($CASH$) MACHINE by Equita Sim
- Sonae - 4Q23 Results: Food retail remains healthy; reiterating Buy by JB Capital Markets
- Merlin Properties –FB roadshow : une stratégie climat innovante et crédible by Oddo BHF
- ON AIR: Innovation Through the Woof KOL call, Mar 20 by BNP Paribas Exane
- Adjusting forecasts and valuation by BNP Paribas Exane
- FY 23 results beat - sale of storage and special dividend by BNP Paribas Exane